Skip to content
Research Article Open access CC BY 4.0

Adipocytokines, Receptor Activator of Nuclear Factor-κB Ligand, and Midkine: Intricate Biomarkers Network Involved in Pathogenesis and Activity of Rheumatoid Arthritis in Egyptians

Nema Ali Soliman, Walaa Arafa Keshk, Radwa Mostafa Elkhouly

International Journal of Biochemistry Research & Review · pp. 1–9 · Published 22 Jan 2016

10.9734/IJBCRR/2016/23824

Abstract

Background: Rheumatoid arthritis (RA) is a common autoimmune disease in which a heterogeneous course and different pathogenic mechanisms are implicated in the development of chronic inflammation and subsequent joint damage. Early diagnosis and timely detection of RA progression are of global challenges. However, the lack of sensitivity of the currently available biomarkers has impaired the ability to implement potentially effective therapy in a timely manner. Adipocytokines such as adiponectin, and visfatin have recently emerged as pro-inflammatory mediators involved in the pathophysiology of RA, however they still a matter of debate. Aim: This current study went further to investigate the roles of Adipocytokines, receptor activator of nuclear factor kappa-B ligand (RANKL) levels and midkine (MDK) gene expression axis in patients with early untreated RA and their implication in disease activity monitoring. Methodology: Forty newly diagnosed untreated patients with RA (20 patients with active RA and 20 patients with inactive RA) in addition to twenty apparently healthy age, sex and race matched controls were enrolled in this study. Serum tumor necrosis factor-alpha (TNF-α), adiponectin, visfatin and RANKL levels by immunoassay and MDK mRNA level in peripheral blood by real-time PCR were assessed. Results: TNF-α, adiponectin, visfatin and RANKL levels as well as peripheral blood MDK mRNA levels were significantly increased in patients RA with higher values were for active RA with significant positive correlations to disease activity score 28 (DAS-28). Conclusion: Adipocytokines, RANKL and MDK axis has a role in RA pathogenesis, early diagnosis and disease activity. These results may open new avenues for developing preventive and therapeutic strategies for RA.

Rheumatoid arthritis tumor necrosis factor-α adiponectin visfatin receptor activator of NF-κB ligand midkine

References (25)

  1. 1 The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis [DOI]
  2. 2 Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis [DOI]
  3. 3 The Pathogenesis of Rheumatoid Arthritis [DOI]
  4. 4 Evidence that cytokines play a role in rheumatoid arthritis [DOI]
  5. 5 Obesity in autoimmune diseases: Not a passive bystander [DOI]
  6. 6 The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis [DOI]
  7. 7 Adiponectin Stimulates RANKL and Inhibits OPG Expression in Human Osteoblasts Through the MAPK Signaling Pathway [DOI]
  8. 8 The Potential of Adiponectin in Driving Arthritis [DOI]
  9. 9 Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases [DOI]
  10. 10 Interleukin‐22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts [DOI]
  11. 11 Functional Receptors and Intracellular Signal Pathways of Midkine (MK) and Pleiotrophin (PTN) [DOI]
  12. 12 Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis [DOI]
  13. 13 Adiponectin stimulates prostaglandin E 2 production in rheumatoid arthritis synovial fibroblasts [DOI]
  14. 14 Visfatin/Pre-B-cell Colony-enhancing Factor (PBEF), a Proinflammatory and Cell Motility-changing Factor in Rheumatoid Arthritis [DOI]
  15. 15 Recruitment of insulin receptor substrate-1 and activation of NF-κB essential for midkine growth signaling through anaplastic lymphoma kinase [DOI]
  16. 16 A novel therapeutic approach targeting rheumatoid arthritis by combined administration of morin, a dietary flavanol and non-steroidal anti-inflammatory drug indomethacin with reference to pro-inflammatory cytokines, inflammatory enzymes, RANKL and transcription factors [DOI]
  17. 17 Midkine Inhibits Inducible Regulatory T Cell Differentiation by Suppressing the Development of Tolerogenic Dendritic Cells [DOI]
  18. 18 Adherence to Anti–Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis [DOI]
  19. 19 Decreased Circulating Visfatin Is Associated with Improved Disease Activity in Early Rheumatoid Arthritis: Data from the PERAC Cohort [DOI]
  20. 20 Inhibitory effect of CD147/HAb18 monoclonal antibody on cartilage erosion and synovitis in the SCID mouse model for rheumatoid arthritis [DOI]
  21. 21 New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol [DOI]
  22. 22 Genetic and ultrastructural demonstration of strong reversibility in human mesenchymal stem cell [DOI]
  23. 23 Plasma and synovial fluid adipocytokines in patients with rheumatoid arthritis and osteoarthritis.
  24. 24 Midkine as a molecular target: Comparison of effects of chondroitin sulfate E and siRNA [DOI]
  25. 25 The role of OPG/RANKL/RANK in bone destruction in rheumatoid arthritis

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

75

Page views

0

PDF downloads

45

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.